TY - CHAP
T1 - Sexual dysfunction
T2 - Neurbiological, pharmacological, and genetic consideration
AU - Mustanski, Brian
AU - Bancroft, John
PY - 2006
Y1 - 2006
N2 - Sexual side-effects are common with various types of psychotropic medications, especially antidepressants and anti-psychotic agents. Such sideeffects not only affect quality of life, they are also relevant to drug compliance, of particular importance in the long-term treatment of psychotic illnesses like schizophrenia. There is however, considerable individual variability in the pattern and severity of such side-effects, raising the question of whether genetic factors may be relevant. Pharmacogenetic research on sexual dysfunctions could be productive in answering several important questions: How much positive predictive power could genetic information provide in forecasting sexual sideeffects? What particular neurotransmitter receptors or transporters are related to such sexual side-effects? How can this line of research be used to help answer basic questions about the neurobiology of sexual dysfunction? Unfortunately, none of these questions can be answered as of yet. Most pharmacogenetic investigations have focused on predicting primary outcomes; recent studies have started to focus on side-effects, but so far sexual side-effects have either not been considered or not distinguished from other types of side-effects. This chapter will focus on possible candidates for pharmacogenetic investigations of sexual side-effects, especially in relation to antidepressant and anti-psychotic drugs.
AB - Sexual side-effects are common with various types of psychotropic medications, especially antidepressants and anti-psychotic agents. Such sideeffects not only affect quality of life, they are also relevant to drug compliance, of particular importance in the long-term treatment of psychotic illnesses like schizophrenia. There is however, considerable individual variability in the pattern and severity of such side-effects, raising the question of whether genetic factors may be relevant. Pharmacogenetic research on sexual dysfunctions could be productive in answering several important questions: How much positive predictive power could genetic information provide in forecasting sexual sideeffects? What particular neurotransmitter receptors or transporters are related to such sexual side-effects? How can this line of research be used to help answer basic questions about the neurobiology of sexual dysfunction? Unfortunately, none of these questions can be answered as of yet. Most pharmacogenetic investigations have focused on predicting primary outcomes; recent studies have started to focus on side-effects, but so far sexual side-effects have either not been considered or not distinguished from other types of side-effects. This chapter will focus on possible candidates for pharmacogenetic investigations of sexual side-effects, especially in relation to antidepressant and anti-psychotic drugs.
UR - http://www.scopus.com/inward/record.url?scp=55249122859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55249122859&partnerID=8YFLogxK
U2 - 10.1007/0-387-34577-2_17
DO - 10.1007/0-387-34577-2_17
M3 - Chapter
AN - SCOPUS:55249122859
SN - 0387307931
SN - 9780387307930
SP - 479
EP - 494
BT - Psychopharmacogenetics
PB - Springer US
ER -